E. coli scare spawns therapy search.
Service
R F
RF
D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001427:Bacterial Toxins / Q000276:immunology / Q000378:metabolism; D001428:Bacterial Vaccines / Q000276:immunology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D004926:Escherichia coli / Q000276:immunology*; D004927:Escherichia coli Infections / Q000150:complications / Q000628:therapy*; D006471:Gastrointestinal Hemorrhage / Q000382:microbiology / Q000628:therapy; D006017:Glycolipids / Q000378:metabolism; D006463:Hemolytic-Uremic Syndrome / Q000382:microbiology / Q000628:therapy*; D006801:Humans; D009844:Oligosaccharides / Q000378:metabolism / Q000627:therapeutic use*; D011956:Receptors, Cell Surface / Q000378:metabolism; D022622:Shiga Toxin 1; D022641:Shiga Toxin 2
D000907:Antibodies, Bacterial; D001427:Bacterial Toxins; D001428:Bacterial Vaccines; D006017:Glycolipids; D009844:Oligosaccharides; D011956:Receptors, Cell Surface; D022622:Shiga Toxin 1; D022641:Shiga Toxin 2; C068556:Shiga-like toxin receptor